<DOC>
	<DOCNO>NCT02112916</DOCNO>
	<brief_summary>This randomized phase III trial compare well combination chemotherapy work give without bortezomib treat patient newly diagnose T-cell acute lymphoblastic leukemia stage II-IV T-cell lymphoblastic lymphoma . Bortezomib may help reduce number leukemia lymphoma cell block enzymes need cell growth . It may also help chemotherapy work well make cancer cell sensitive drug . It yet know give standard chemotherapy without bortezomib effective treat T-cell acute lymphoblastic leukemia T-cell lymphoblastic lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bortezomib Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia Stage II-IV T-Cell Lymphoblastic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare event-free survival ( EFS ) patient newly diagnose T-cell acute lymphoblastic leukemia ( T-ALL ) T-cell lymphoblastic lymphoma ( T-LLy ) randomize modify augment Berlin-Frankfurt-MÃ¼nster ( ABFM ) backbone versus bortezomib plus modified ABFM backbone . SECONDARY OBJECTIVES : I . To determine safety feasibility modify standard therapy T-ALL T-LLy base result UKALL 2003 , include dexamethasone-based induction , additional dos pegaspargase ( PEG-ASP ) induction delay intensification ( DI ) , dexamethasone pulse maintenance therapy . II . To determine prophylactic ( presymptomatic ) cranial irradiation ( CRT ) safely effectively eliminate 85-90 % T-ALL patient classified standard intermediate risk . III . To determine proportion end consolidation ( EOC ) minimal residual disease ( MRD ) &gt; = 0.1 % T-ALL patient become MRD negative ( undetectable flow cytometry ) intensification chemotherapy , use three high risk ( HR ) BFM block , compare EFS patient become MRD negative three HR BFM block continue chemotherapy continue detectable MRD eligible treatment strategy , include hematopoietic stem cell transplant ( HSCT ) . Similarly , compare EFS high risk ( induction failure ) T-LLy patient treat HR BFM intensification block partial complete response ( PR CR ) respond ( NR ) . TERTIARY OBJECTIVES : I . To investigate prognostic significance day 29 bone marrow ( BM ) MRD T-LLy patient . II . To determine protein expression pattern predict bortezomib response drug resistance T-ALL . III . To analyze target relevant signal pathways T-ALL blast , focus early T cell precursor ( ETP ) acute lymphoblastic leukemia ( ALL ) . OUTLINE : Patients randomize 1 2 treatment arm . INDUCTION ARM A : Patients receive cytarabine intrathecally ( IT ) time diagnostic lumbar puncture ( within 72 hour start protocol therapy ) OR day 1 ; vincristine sulfate intravenously ( IV ) 1 minute day 1 , 8 , 15 , 22 ; dexamethasone orally ( PO ) twice daily ( BID ) day 1-28 ( taper ) ; daunorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 , 22 ; pegaspargase IV 1-2 hour day 4 18 ; methotrexate IT day 8 29 ( day 15 22 central nervous system 3 involvement [ CNS3 ] T-ALL patient ) . INDUCTION ARM B : Patients receive bortezomib IV day 1 , 4 , 8 , 11 ; cytarabine , vincristine sulfate , dexamethasone , daunorubicin hydrochloride , pegaspargase , methotrexate Induction Arm A . CONSOLIDATION : Beginning day 36 Induction , patient receive methotrexate IT day 1 , 8 , 15 , 22 ( day 1 8 CNS3 T-ALL CNS3 T-LLy patient ) ; cyclophosphamide IV 30-60 minute day 1 29 ; cytarabine IV 1-30 minute subcutaneously ( SC ) day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO daily ( QD ) day 1-14 29-42 ; pegaspargase IV 1-2 hour day 15 43 ; vincristine sulfate IV day 15 , 22 , 43 , 50 . Patients persistent testicular disease undergo radiation therapy . Patients assign subsequent therapy accord risk assignment . Patients standard risk ( SR ) disease receive Interim Maintenance Capizzi methotrexate ( CMTX ) ; patient intermediate risk ( IR ) disease receive Interim Maintenance high-dose methotrexate ( HDMTX ) , Delayed Intensification , Interim Maintenance CMTX ; patient high risk ( VHR ) disease receive 3 HR Intensification Blocks , Delayed Intensification , Interim Maintenance CMTX . CMTX INTERIM MAINTENANCE : Patients receive vincristine sulfate IV day 1 , 11 , 21 , 31 , 41 ; methotrexate IV 2-5 minute ( undiluted ) 10-15 minute ( dilute ) day 1 , 11 , 21 , 31 , 41 ; pegaspargase IV 1-2 hour day 2 22 ; methotrexate IT day 1 31 . The next course ( base risk assignment ) begin day 57 blood count recover ( whichever occurs later ) . DELAYED INTENSIFICATION ARM A : Patients receive vincristine sulfate IV day 1 , 8 , 15 , 43 , 50 ; dexamethasone PO BID IV day 1-7 15-21 ; doxorubicin hydrochloride IV 15 minute day , 1 , 8 , 15 ; pegaspargase IV 1-2 hour day 4 , 18 , 43 ; methotrexate IT day 1 , 29 , 36 ; cyclophosphamide IV 30-60 minute day 29 ; cytarabine IV 1-30 minute SC day 29-32 36-39 ; thioguanine PO day 29-42 . The next course ( base risk assignment ) begin day 64 blood count recover ( whichever occurs later ) . DELAYED INTENSIFICATION ARM B : Patients receive bortezomib IV day 1 , 4 , 15 , 18 ; vincristine sulfate , dexamethasone , doxorubicin hydrochloride , pegaspargase , methotrexate , cyclophosphamide , cytarabine , thioguanine Delayed Intensification Arm A . The next course ( base risk assignment ) begin day 64 blood count recover ( whichever occurs later ) . HDMTX INTERIM MAINTENANCE : Patients receive high-dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 ; leucovorin calcium IV PO day 3-4 , 17-18 , 31-32 , 45-46 ; vincristine sulfate IV day 1 , 15 , 29 , 43 ; mercaptopurine PO QD day 1-56 ; methotrexate IT day 1 29 . The next course ( base randomization assignment ) begin day 57 blood count recover ( whichever occurs later ) . INTENSIFICATION BLOCK I : Patients receive dexamethasone IV PO BID day 1-5 ; high-dose methotrexate IV 24 hour day 1 ; leucovorin calcium IV PO day 3-4 ; vincristine sulfate IV day 1 6 ; cyclophosphamide IV 1-6 hour day 2-4 ; high-dose cytarabine IV 3 hour every 12 hour day 5 ; pegaspargase IV 1-2 hour day 6 ; triple IT therapy comprise methotrexate IT , hydrocortisone IT , cytarabine IT day 1 . The next course ( Intensification Block II ) begin day 22 blood count recover ( whichever occurs later ) . INTENSIFICATION BLOCK II : Patients receive dexamethasone PO BID IV day 1-5 ; high-dose methotrexate IV 24 hour day 1 ; leucovorin calcium PO IV day 3-4 ; vincristine sulfate IV day 1 6 ; ifosfamide IV 1 hour every 12 hour day 2-4 ; daunorubicin hydrochloride IV 30 minute day 5 ; pegaspargase IV 1-2 hour day 6 ; triple IT therapy day 1 Intensification Block I . The next course ( Intensification Block III ) begin day 22 blood count recover ( whichever occurs later ) . INTENSIFICATION BLOCK III : Patients receive dexamethasone PO BID IV day 1-5 ; high-dose cytarabine IV 3 hour every 12 hour day 1-2 ; etoposide IV 1-2 hour every 12 hour day 3-5 ; pegaspargase IV 1-2 hour day 6 ; triple IT therapy day 5 Intensification Block I . The next course ( base randomization ) begin day 22 blood count recover ( whichever occurs later ) . MAINTENANCE THERAPY : All patient receive vincristine sulfate IV day 1 , 29 , 57 ; dexamethasone PO BID IV day 1-5 , 29-33 , 57-61 ; mercaptopurine PO day 1-84 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ( omit day 29 SR patient first 4 course ) ; methotrexate IT day 1 ( day 29 first 4 course SR patient first 2 course IR patient ) . Patients CNS3 IR disease also undergo cranial radiation therapy first 4 week ( course 1 ) . Treatment female patient T-ALL patient T-LLY repeat every 12 week 2 year start Interim Maintenance ( week 119 ) . Treatment male patient T-ALL repeat every 12 week 3 year start Interim Maintenance ( week 171 ) . All treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>TALL : TALL patient must enrol Project Every Child ( APEC14B1 ) prior treatment enrollment AALL1231 TLLy : Project : Every Child ( APEC14B1 ) available , TLLy patient must enrol APEC14B1 prior treatment enrollment AALL1231 Patients must newly diagnose Tlymphoblastic leukemia ( TALL ) Tlymphoblastic lymphoma ( TLLy ) stag IIIV Note : diagnosis TALL establish leukemic blast lack myeloperoxidase evidence Blineage derivation ( cluster differentiation [ CD ] 19/CD22/CD20 ) , express either surface cytoplasmic CD3 two antigen CD8 , CD7 , CD5 , CD4 , CD2 CD1a , present either peripheral blood &gt; 25 % bone marrow ; surface CD3 express leukemic cell , additional marker immaturity , include terminal deoxynucleotidyl transferase ( TdT ) , CD34 CD99 assess expression ; case uncertain expression receive additional review within appropriate Children 's Oncology Group ( COG ) reference laboratory For TLLy patient tissue available flow cytometry , criterion diagnosis analogous TALL ; tissue process mean ( i.e . paraffin block ) , methodology criterion immunophenotypic analysis establish diagnosis TLLy define submit institution accept All patient and/or parent legal guardian must sign write informed consent ; assent , appropriate , obtained accord institutional guideline Patients must receive cytotoxic chemotherapy either current diagnosis TALL , TLLy cancer diagnosis prior initiation protocol therapy AALL1231 , exception : Steroid pretreatment : prednisone methylprednisolone = &lt; 120 hour ( 5 day ) 7 day prior initiate induction chemotherapy = &lt; 336 hour ( 14 day ) 28 day prior initiate induction chemotherapy ; prior exposure ANY steroid occur &gt; 28 day initiation protocol therapy affect eligibility ; dose prednisone methylprednisolone affect eligibility Intrathecal cytarabine ( CNS status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment ) system chemotherapy must begin 72 hour IT therapy ; 600 cGy chest irradiation , medically necessary Pretreatment dexamethasone 28 day prior initiation protocol therapy allow exception single dose dexamethasone use sedation prevent treat airway edema Preexisting &gt; = grade 2 sensory motor peripheral neurotoxicity Uncontrolled seizure disorder Diagnosis Down syndrome ( Trisomy 21 ) Patients pregnant ; pregnancy test require female patient childbearing potential Lactating female plan breastfeed Sexually active patient reproductive potential agree use effective contraceptive method duration study participation Patient hypersensitivity bortezomib , boron , mannitol Serious medical psychiatric illness likely interfere participation clinical study Participation clinical trial investigational agent include trial , within 14 day start trial within 30 day dose bortezomib</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>